Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Overactive Bladder Age: Adult and elderly |
Dose: Tablet – 4 mg Frequency: once daily Duration: 2-8 weeks Note: may be increased to 8 mg once daily. Maximum: 8 mg once daily. |
|
Indication: Overactive Bladder Age: Adult and elderly Condition: Mild-to-moderate Hepatic impairment (Child Pugh A to B) |
Dose: Tablet – 4 mg Frequency: once daily Duration: 2-8 weeks Note: No dosage adjustment necessary. may be increased to 8 mg once daily. Maximum: 8 mg once daily. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Pediatric Neurogenic Detrusor Overactivity Age: less than 6 years |
Dose: Not established Note: Not established |
|
Indication: Pediatric Neurogenic Detrusor Overactivity Age: greater than 6 years |
Dose: Not established Note: Not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Mild-to-moderate renal impairment (creatinine clearance greater than 30 mL/min) |
Dose: Tablet – Not specified Note: No dosage adjustment necessary |
|
Condition: Severe renal impairment (creatinine clearance less than 30 mL/min) |
Dose: Tablet – 4 mg Frequency: once a day Note: Not to exceed 4 mg by mouth once a day |
Administration
- May be taken with or without food
- Take at same time each day
Side Effect
- Adult overactive bladder
- Dry mouth (18.8-34.6%)
- Pediatric neurogenic detrusor overactivity
- Diarrhea (7.1-11.9%)
- Adult overactive bladder
- Constipation (4.2-6%)
- Dyspepsia (1.6-2.3%)
- Urinary Tract Infection (UTI) (3.2-4.2%)
- Xerophthalmia (1.4-3.7%)
- Upper respiratory tract infection (URTI) (1.8-2.5%)
- Dysuria (1.3-1.6%)
- Urinary retention (1.1-1.4%)
- Dry throat (0.9-2.3%)
- Insomnia (0.4-1.3%)
- Back pain (0.9-2%)
- Nausea (0.7-1.9%)
- ncreased ALT (0.5-1.2%)
- Increased GGT (0.4-1.2%)
- Peripheral edema (0.7-1.2%)
- Upper abdominal pain (0.5-1.1%)
- Rash (0.7-1.1%)
- Pediatric neurogenic detrusor overactivity
- Urinary Tract Infection (UTI) (2.4-9.5%)
- Dry mouth (7.1-9.5%)
- Constipation (7.1-7.1%)
- Abdominal pain (4.8-2.4%)
- Weight increased (0-4.8%)
- Headache (4.8-7.1%)
- Ophthalmological reactions (6.1%)
- Increased heart rate compared to baseline (8.1-12.2% week 4, 7.6-11.4% week 12, 3.3-2.7% week 24)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Antimuscarinic agents
|
Increased frequency &/or severity of adverse reactions & other anticholinergic effects
|
|
Anticholinergic agents
|
Altered absorption
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.